Table 1 |
|||||||
|
Main clinical data of SLE patients studied |
|||||||
|
Patient |
Age (years)/gender |
Disease duration (years) |
Main clinical manifestation |
Nephritis stage/durationa |
Disease activityb |
Previous therapy |
Current therapyc |
|
|
|||||||
|
1 |
41/F |
15 |
Ou, Ar, Le, Ly |
IV/8 |
12 |
GC, Cyc, Aza |
GC, Aza |
|
2 |
24/M |
4 |
Er, Ph, Le |
IV/4 |
10 |
GC, Aza, Mmf, CsA |
GC, Mmf |
|
3 |
36/F |
6 |
Er, Ph, Ou, Ar, Le, Ly |
III/6 |
14 |
GC, Aza, CsA |
GC, Aza, Mtx |
|
4 |
19/M |
5 |
Le |
IV/4 |
8 |
GC, Cyc, Mmf |
GC |
|
5 |
56/F |
12 |
Er, Ph, Ou, Se, Ar |
IV/3 |
15 |
GC, Cyc, Mmf, Aza |
GC, Mmf |
|
6 |
9/M |
1 |
Er, Ph, Se, Ar |
IV/1 |
12 |
GC, Mmf, Mtx, Aza, Cy |
GC, Aza, Mtx, Mmf |
|
7 |
26/F |
11 |
Er, Ph, Ou, Se, Ar, Le |
IV/4 |
10 |
GC, Mtx, Aza |
GC, Mtx, Aza |
|
8 |
31/F |
16 |
Ph, Ou, Se, Ar, CNS |
IV/8 |
10 |
GC, Cyc, Lfm, Aza, Mtx, Mmf |
GC, Aza, Mtx, Mmf, Cyc |
|
9 |
23/F |
3 |
Ph, Ou, Se, Ar, CNS |
IV/3 |
12 |
GC, Mmf, Aza, Cyc, Mtx |
GC, Mtx, Mmf |
|
10 |
32/F |
6 |
Er, Ph, Ou, Ar, Ly |
IV/6 |
8 |
GC, Mtx, Aza, Cyc |
Aza |
|
11 |
24/F |
2 |
Er, Ph, Ou, Se |
III/2 |
9 |
GC, Mtx, Aza |
Aza, Mtx, Mmf |
|
12 |
27/F |
13 |
Er, Ph, Ou, Se, Ly |
IV/13 |
19 |
GC, Mmf, Cyc, Aza |
GC, Aza, Mtx, Mmf |
|
13 |
43/F |
6 |
Er, Ph, Le |
IV/6 |
9 |
GC, Mtx, Aza, Pdn |
Mtx |
|
14 |
21/F |
8 |
Er, Ph, Ou, Se, Ly |
V/8 |
9 |
GC, Mtx, Aza, Cyc, Mmf |
None |
|
15 |
36/F |
1 |
Er, Ph, Ly |
V/1 |
10 |
GC, Aza |
Aza |
|
16 |
25/F |
1 |
Er, Ou, Se, Ly, CNS |
IV/1 |
11 |
GC, Aza, Mtx |
GC |
|
17 |
33/F |
8 |
Er, Ph, Ou, Se, Ar, Le |
IV/8 |
10 |
GC, Aza, Mtx, Mmf, Cq |
GC, Aza, Mtx, Mmf |
|
18d |
28/F |
3 |
Er, Ph, Ou, Se, Le, Ly |
IV/3 |
9 |
GC, Cyc, Aza, Mmf, Mtx, Cq |
GC, Aza, Mtx, Mmf |
|
19 |
40/F |
4 |
Er, Ph, Ou, Se, Ar |
IV/4 |
10 |
GC, Aza, Mtx |
Aza |
|
20 |
19/F |
1 |
A, Le, Ly |
IV/1 |
10 |
GC, Aza, Mtx, Mmf |
GC, Aza, Mmf |
|
21 |
24/F |
4 |
Er, Ph, Le |
IV/3 |
10 |
GC, Aza, Mtx, Mmf, Cyc |
GC, Aza, Mtx |
|
22 |
22/F |
1 |
Ou, Ar, Le, Se |
IV/1 |
10 |
GC, Aza, Mtx, Mmf, Cq |
GC, Aza, Mtx, Mmf |
|
|
|||||||
|
aAccording to the WHO classification [33]; duration is in years. bAccording to the MEX-SLEDAI index. cImmunosuppressive therapy to which Rituximab was added. dThis patient had invasive histoplasmosis of the lungs with massive hemorrhage and mucormycosis of a coronary artery; she died at day 70 of Rituximab therapy. Ar, arthritis; Aza, azathioprine; Cfm, cyclophosphamide; Cq, chloroquine; CNS, central nervous system disease; Er, erythema; GC, glucocorticoids; Le, leukopenia; Lfm, leflunomide; Ly, severe lymphopenia (lymphocyte count <1,000 cells/mm3); Mmf, mycophenolate mofetil; Mtx, methotrexate; N, nephritis; Ou, oral ulcers; Ph, photosensitivity; Se, serositis. |
|||||||
|
Vigna-Perez et al. Arthritis Research & Therapy 2006 8:R83 doi:10.1186/ar1954 |
|||||||
